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Central role for liver X receptor in insulin-mediated
activation of Srebp-1c transcription and stimulation
of fatty acid synthesis in liver
Guoxun Chen, Guosheng Liang, Jiafu Ou, Joseph L. Goldstein*, and Michael S. Brown*
Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TX 75390-9046
Contributed by Michael S. Brown, June 21, 2004
Transcription of the gene encoding sterol regulatory element-
binding protein 1c (SREBP-1c) is known to be activated by insulin
in the liver. The resultant SREBP-1c protein activates transcription
of the genes required for fatty acid synthesis. Here, we use
SREBP-1c promoter reporter constructs to dissect the mechanism of
insulin activation in freshly isolated rat hepatocytes. The data
show that a complete insulin response (increase of 6- to 11-fold)
requires two binding sites for liver X receptors (LXRs), which are
nuclear receptors that are activated by oxygenated sterols. Dis-
ruption of these binding sites did not lower basal transcription but
severely reduced the response to insulin. In contrast, disruption of
the closely linked binding sites for SREBPs and nuclear factor Y
lowered basal transcription drastically but still permitted a 4- to
7-fold increase in response to insulin. Arachidonic acid, an inhibitor
of LXR activation, blocked the response to insulin. We conclude
that insulin activates the SREBP-1c promoter primarily by increas-
ing the activity of LXRs, possibly through production of a ligand
that activates LXRs or their heterodimerizing partner, the retinoid
X receptor. Nuclear SREBPs and nuclear factor Y play permissive
roles.
E levated hepatic synthesis of fatty acids and triglycerides(lipogenesis) is a troublesome consequence of hyperinsulin-
emia observed in obesity and type 2 diabetes mellitus. The
increased flux of triglycerides from liver to peripheral tissues
interferes with glucose usage, thereby accentuating insulin re-
sistance and producing further hyperinsulinemia (1, 2). The
elevated hepatic lipogenesis is the result of the elevated insulin
levels, which enhance transcription of lipogenic genes in liver. At
the same time that the liver is responding to one action of insulin
(lipogenesis), the organ becomes resistant to another action of
insulin, namely, suppression of gluconeogenesis. The failure to
suppress hepatic gluconeogenesis coupled with decreased pe-
ripheral glucose uptake accentuates the hyperglycemia and
increases insulin secretion, further enhancing lipogenesis and
completing a vicious cycle (1, 3). This vicious cycle has been
demonstrated in two mouse models of insulin resistance, both of
which are associated with a deficiency of the adipocyte hormone,
leptin: the obob mouse and the lipodystrophic aP2 sterol
regulatory element-binding protein 1c (aP2-SREBP-1c) trans-
genic mouse (3).
The insulin-responsive transcription factor responsible for
insulin-enhanced lipogenesis has been identified as SREBP-1c
(4, 5). SREBP-1c is one of three SREBPs that belong to the basic
helix–loop–helix-leucine zipper family of transcription factors.
Two of the SREBPs (SREBP-1a and SREBP-1c) are derived
from one gene through the use of alternative promoters and
transcription start sites that produce two isoforms that differ by
the first exon (6). In the fed state, SREBP-1c is the main
SREBP-1 transcript (mouse liver 1c-to-1a ratio is 9:1). Both of
the SREBP-1 isoforms preferentially activate fatty acid and
triglyceride synthesis (6). SREBP-2 is encoded by a different
gene (4), and it preferentially activates cholesterol synthesis,
although functional overlap exists.
Recent reviews have summarized the studies demonstrating
that insulin selectively stimulates Srebp-1c gene transcription in
liver, and that SREBP-1c in turn mediates insulin-stimulated
fatty acid synthesis (4, 5). In brief, insulin was shown to increase
SREBP-1c mRNA levels concomitant with its ability to elevate
mRNA levels for fatty acid biosynthetic genes in hepatocytes (7),
and a dominant-negative form of SREBP-1c blocked the insulin
effect on the fatty acid biosynthetic genes (8). The insulin effect
on SREBP-1c mRNA was blocked when cAMP levels were
elevated by glucagon, and this block was associated with a decline
in acetyl-CoA carboxylase and fatty acid synthetase, the two key
enzymes of fatty acid biosynthesis (3). Hereafter, we refer to
these two mRNAs as lipogenic mRNAs. In the livers of living
rodents, SREBP-1c mRNA levels were shown to decline when
insulin fell as a result of fasting or treatment with streptozotocin,
and this fall was paralleled by decreases in lipogenic mRNAs (7,
9). The opposite result was observed when insulin was admin-
istered to the streptozotocin-treated rats.
In livers of lipodystrophic and obob mice, SREBP-1c mRNA
levels were elevated as a result of hyperinsulinemia secondary to
leptin deficiency (10). Leptin treatment normalized plasma
insulin. As a result, SREBP-1c mRNA levels fell, the mRNAs for
lipogenic genes declined, and the fatty liver resolved.
The crucial role of SREBP-1c in lipogenesis was demonstrated
conclusively by experiments with mice deficient in SREBP
cleavage-activating protein (SCAP), a protein that is necessary
to process SREBPs to their active nuclear forms (11). When
these mice were fasted and then refed a high-carbohydrate diet,
they showed a dramatic reduction in the insulin-induced increase
in lipogenic mRNA levels. Similar but less dramatic results were
observed in knockout mice that lack the SREBP-1c isoform (12).
In addition to regulation by insulin and glucagon, hepatic
SREBP-1c mRNA levels are increased by agonists of liver X
receptors (LXRs), nuclear hormone receptors that form active
heterodimers with retinoid X receptors (RXRs) (13–15). The
primary activators of LXRs are oxygenated intermediates in
cholesterol synthesis (16). LXR activity is inhibited competi-
tively by polyunsaturated fatty acids (17). A synthetic LXR
ligand, T0901317, increases hepatic SREBP-1c mRNA levels
and thereby increases mRNAs for lipogenic enzymes when
administered to mice. The result is fatty liver and hypertriglyc-
eridemia (13, 14). Similar results are obtained with agonists of
RXR, the heterodimerizing partner of the LXRs (13). Gene-
knockout mice lacking SREBP-1c show a blunted increase in
lipogenic mRNAs in response to T0901317, confirming the role
of SREBP-1c in this response (12).
Abbreviations: LXR, liver X receptor; LXRE, LXR element; NF-Y, nuclear factor Y; RXR,
retinoid X receptor; SRE, sterol regulatory element; SREBP, sterol regulatory element-
binding protein; SCAP, SREBP cleavage-activating protein.
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The above studies point to regulation of Srebp-1c transcription
as a central event in lipid homeostasis, and studies have begun
to delineate the cis elements that are responsible for this
regulation. Relevant elements of the mouse (18, 19) and rat (20)
proximal SREBP-1c promoter have been mapped by gene
reporter studies in cultured cells. An analysis of the mouse
SREBP-1c promoter revealed two putative LXR elements
(LXREs), one putative nuclear factor Y (NF-Y) binding site,
and one sterol regulatory element (SRE) (18, 19). All of these
elements are highly conserved in the human and rat genomes.
The presence of an SRE suggests that SREBP-1c mRNA can
increase in response to nuclear SREBPs, creating a feed-forward
activation. This view was supported by studies showing that the
SREBP-1c reporter construct was stimulated by cotransfection
of plasmids encoding truncated nuclear forms of SREBP-1c,
SREBP-1a, or SREBP-2 (19). Thus far, SREBPs always activate
target gene transcription in concert with a constitutively active
transcription factor, typically NF-Y or Sp1, which binds at a
nearby site (21–23). In the case of the SREBP-1c promoter, the
SRE is surrounded by a 5 NF-Y site and a 3 Sp1 site. The NF-Y
site was shown to be required for the SREBP-1c promoter to be
stimulated by nuclear SREBPs (19).
The role of the LXREs in Srebp-1c transcription was estab-
lished by the finding of a blunted response to T0901317 when
these elements had been scrambled by in vitro mutagenesis (13).
The conclusion of all of these studies is that Srebp-1c transcrip-
tion can be regulated positively by nuclear SREBPs (together
with NF-Y andor Sp1) and by LXR agonists through identifi-
able elements in the SREBP-1c proximal promoter. None of the
earlier studies addressed the mechanism of the insulin response.
The current studies were designed to explore the mechanism
by which insulin stimulates the SREBP-1c promoter. We were
unable to find a cultured hepatocyte cell line that retains the
ability to respond to insulin by up-regulating SREBP-1c mRNA
levels. Therefore, we performed these studies in freshly isolated
rat hepatocytes. The results indicate that the SREBP-1c pro-
moter does not have a separate insulin response element, and
that insulin acts primarily through the LXR elements in a
reaction that requires the NF-Y site and the SRE.
Methods
Materials. We obtained bovine insulin (catalog no. I 6634),
dexamethasone (no. D 4902), 3,3,5-triiodo-L-thyronine (no. T
5516), and arachidonic acid (no. A 9673) from Sigma; lipofectin
(no. 18292-037) and medium 199 (no. 11150-059) from Invitro-
gen; PBS (no. 21-031-CV), DMEM (no. 10-014-CV), and RPMI
medium 1640 (no. 10-040-CV) from Mediatech (Herndon, VA);
60-mm collagen-I-coated dishes (no. 356401) from Becton Dick-
inson Labware; jetPEI transfection reagent (no. GDSP10110)
from Qbiogene (Carlsbad, CA); T0901317 compound (lot no.
54-143-1) from J-Star Research (South Plainfield, NJ); and FCS
from Atlanta Biologicals (Norcross, GA). A stock solution of
sodium arachidonate bound to defatted BSA was prepared as
described in ref. 17.
Insulin and LXR Agonist. Stock solutions of 0.1 mM insulin were
prepared in distilled water adjusted to pH 4.5 with glacial acetic
acid, stored at 4°C, and used within 3 months. Stock solutions of
1 mM T0901317 (synthetic LXR agonist) were prepared in
DMSO, stored at 20°C, and used within 1 month. Stock
solutions of 10 mM compactin were prepared as described (24),
stored at 80°C, and used fresh for each experiment.
Mouse SREBP-1c Promoter–Luciferase Constructs. A series of plas-
mids, constructed by standard techniques of recombinant DNA
engineering (25), contained fragments of the mouse SREBP-1c
promoter, extending for various distances in the 5 direction and
terminating either at the A of the initiation codon in exon 1c
(plasmids A–C) or at the end of the first codon of exon 2
(plasmids D–I), as shown in Fig. 1. These fragments were cloned
by PCR amplification using mouse SM-1 embryonic stem cell
genomic DNA as the template (12). Primers used for these PCRs
were based on mouse sequences obtained from the Celera
database (www.celera.com) and confirmed by sequencing (12).
The various amplified fragments were inserted into the pGL3
luciferase reporter vector (Promega).
To construct plasmids m1–m3 (Fig. 2A), we cloned double-
stranded oligonucleotides containing the indicated scramble
mutation (9–12 bp) into plasmid D (Fig. 1D), thus replacing the
corresponding WT sequence. Scramble mutations in plasmids
m4–m30 (Fig. 2 A) were generated with the QuickChange site-
directed mutagenesis kit (Stratagene) using pBP1c(1271)-
luciferase plasmid (13) as the template. Mutagenic oligonucle-
otides 52 bases in length were synthesized so that the 9- to
12-base sequence to be scrambled was located in the center of the
oligonucleotide. The nucleotide sequence of the 9- to 12-bp
scramble was designed to retain the length and base composition
of the WT sequence and to contain novel SmaI or PstI restriction
sites. Plasmids containing the desired scramble mutations were
identified by restriction digestions (XhoISmaI or XhoIPstI)
and DNA sequencing, and the fragments containing the scram-
ble mutations were excised and cloned into plasmid D. To
construct plasmid m31, a double-stranded oligonucleotide con-
taining the LXRE1 mutation in m9 was cloned into plasmid m13
(LXRE2 mutant), thus generating m31 with mutations in both
LXRE1 and LXRE2. To construct plasmids m32–m34, double-
stranded oligonucleotides containing mutations in LXRE1
(m9), LXRE2 (m13), or LXRE1  LXRE2 (m31) were cloned
into plasmid m24 (SRE mutant), thus generating plasmids with
mutations in LXRE1  SRE (m32), LXRE2  SRE (m33), or
LXRE1  LXRE2  SRE (m34), respectively.
All plasmid constructs were verified by restriction endonucle-
ase mapping and DNA sequencing.
Primary Rat Hepatocytes. Male Sprague–Dawley rats (250–350 g;
obtained from Harlan Breeders, Indianapolis) were housed in
colony cages, maintained on a 12-h light12-h dark cycle, and fed
4% MouseRat Diet no. 7001 (Harlan Teklad, Madison, WI).
Nonfasted rats were killed 30 min before the dark cycle, and
primary hepatocytes were isolated by the collagenase method
(26) with modifications as described in ref. 7. The isolated
hepatocytes were plated onto 60-mm collagen-I-coated dishes in
4 ml of medium A (DMEM supplemented with 5% (volvol)
FCS, 100 unitsml sodium penicillin, and 100 gml streptomy-
cin sulfate). The cells were incubated at 37°C in 5% CO2. After
3–4 h, the attached cells were washed once with 4 ml of PBS,
incubated for 14–16 h in medium B (medium 199 supplemented
with 100 nM dexamethasone, 100 nM 3,3,5-triiodo-L-thyronine,
100 unitsml penicillin, and 100 gml streptomycin sulfate)
plus 1 nM insulin, and then used for transfection experiments.
Plasmid Transfection and Luciferase Assays. Duplicate dishes of
hepatocytes were washed once with 4 ml of PBS, incubated in
serum-free RPMI medium 1640 at pH 7.55, and cotransfected
with 2 g per dish of WT or mutant firefly luciferase reporter
plasmids and 0.5 g per dish of a control plasmid phRL-TK
(catalog no. E6241, Promega) encoding the synthetic Renilla
luciferase gene. In all experiments, except that in Fig. 1B,
transfections were performed with Lipofectin (GIBCO), in
which the plasmids were incubated with 2 ml of RPMI medium
1640 for 6 h at 37°C in a 5% CO2 incubator. In Fig. 1B,
transfections were performed with 0.2 ml of jetPEI reagent and
1.8 ml of RMPI medium 1640. After transfection, cells were
washed once with 4 ml of PBS and switched to medium B
containing various reagents as described in the figure legends.
Twenty-one hours later, cells were washed once with 4 ml of PBS
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and harvested by scraping in 0.4 ml of 1 passive lysis buffer (no.
E1941, Promega). Firefly and Renilla luciferase activities in the
cell lysates were measured with the Dual-Luciferase reporter
assay system (Promega) according to the manufacturer’s proto-
col. Photon production was detected as relative light units by
using an Optima II luminometer (MGM Instruments, Hamden,
CT). All values represent the mean of duplicate transfections,
each assayed in triplicate. The amount of firefly luciferase
activity in transfected cell lysates was normalized to the amount
of Renilla luciferase activity from the same test tube.
Results
Fig. 1 A shows a schematic of the 5 end of the mouse Srebp-1
gene, including exons 1a, 1c, and 2. The location of the two
previously identified LXREs, the NF-Y site, and the SRE
proximal to the first exon of SREBP-1c are denoted by the open
and hatched bars, respectively (13, 18). These sites are 10 kb
downstream of exon 1a, the first exon of the SREBP-1a tran-
script, which is not regulated by insulin. As a first step in
identifying the DNA elements that mediate insulin induction of
the SREBP-1c transcript, we introduced the 10-kb promoter
fragment between exons 1a and 1c and various truncations into
the pGL3-Basic reporter vector to generate plasmids A (10 kb),
B (6.5 kb), and C (1.3 kb), each driving production of firefly
luciferase. To assay for insulin action, we introduced plasmids A,
B, and C into primary rat hepatocytes by transfection together
with the Renilla luciferase vector driven by the thymidine kinase
promoter (phRL-TK) as a control. Luciferase activities were
measured after incubation of the cells for 21 h in the presence
or absence of 100 nM insulin. As shown in Fig. 1B, insulin
induced 4-, 5.6-, and 5.1-fold activations of plasmids A, B, and C,
respectively.
To mimic the endogenous Srebp-1c gene structure more
completely, we included the 3-kb intron between exons 1c and
2 in a series of deletion reporter plasmids designated as D
(1271), E (694), F (570), G (368), H (278), and I
(170), as shown in Fig. 1C. When we included this intron, the
relative induction by insulin increased from 5.1-fold (plasmid
C) to 14-fold (plasmid D). Plasmids E, F, and G showed the
same level of basal transcription and fold induction by insulin
as did plasmid D. Deletions in plasmids H and I significantly
reduced the fold induction by insulin from 14 to 4.5 and 1.7,
respectively. These results indicate that the 368-bp promoter
fragment in plasmid G, containing the two LXREs, the NF-Y
site, and the SRE, is sufficient to mediate insulin-induced
Srebp-1c transcription.
To map the insulin-responsive elements more precisely, we
introduced a series of overlapping 9- to 12-bp scramble muta-
tions covering the nucleotide sequence from 364 to 65 into
plasmid D to generate plasmids m1–m30, as shown in Fig. 2 A.
Fig. 2B shows the transcription of the WT plasmid D and mutant
plasmids m1–m30 in the absence or presence of insulin. Fig. 2C
shows the fold induction by insulin. The scramble mutations in
plasmids m7–m9 and m12–m14 destroyed the first and second
LXREs, respectively. These mutations decreased insulin-
induced transcription by 60% without affecting basal tran-
scription significantly. The scramble mutation in plasmid m23
destroyed the NF-Y site, and mutations m24 and m25 destroyed
Fig. 1. Activation of mouse SREBP-1c promoter in rat primary hepatocytes. (A) Schematic of partial mouse Srebp-1c gene, illustrating the upstream regulatory
elements and the intron between exons 1c and 2. The proximal promoter regulatory region is shown with its cis-acting elements: two LXREs (open boxes) and
one NF-Y and one SRE (hatched boxes). (B and C) Deletion analysis of SREBP-1c promoter region and its effects on basal and insulin-induced luciferase activities.
The indicated plasmids were transfected into primary hepatocytes as described in Methods. Six hours after transfection, the medium was switched to medium
B with or without 100 nM insulin and incubated for 21 h, after which the cells were harvested and assayed for dual luciferase activities as described in Methods.
The 100% values for basal activity correspond to the normalized luciferase activity obtained with plasmid A (B) or plasmid D (C) in the absence of insulin. The
fold induction in B and C was calculated as the ratio of normalized luciferase activity in the presence of insulin to that in the absence of insulin. Each value
represents the mean  SEM of three independent transfection experiments (each assayed in duplicate).








the SRE. Each of these mutations decreased basal transcription
to 10% of the WT values, but they still permitted at least a
4-fold induction by insulin. Mutation of the adjacent Sp1 site
(m26) reduced basal transcription slightly but permitted a robust
response to insulin. No other DNA region appeared to be
required for insulin-mediated induction.
The aforementioned nine scramble mutation plasmids were
studied in different transfection experiments. To circumvent any
interexperiment variability, we measured the responses to insulin
in a single transfection experiment in which all of the plasmids
were studied. These experiments were repeated three times, and
the mean results are shown in Fig. 3A. Scramble mutations in
plasmids m7–m9 (LXRE1) and m12–m14 (LXRE2) reduced
insulin-induced luciferase activity from 6.4 in the WT plasmid to
1.5–3.6 without changing the basal level of luciferase activity.
Mutations in plasmids m23 (NF-Y), m24 (SRE), and m25 (SRE
 Sp1) reduced the basal promoter activity by 90%, but insulin
was able to increase the activity by 3- to 5-fold.
Because mutations in LXRE1 (m9), LXRE2 (m13), or SRE
(m24) all affected transcription of the SREBP-1c promoter, we
next studied plasmids containing combinations of mutations
disrupting these three elements (Fig. 3B). Mutating both
LXRE1 and LXRE2 in the same plasmid (m31) had minimal
effects on basal activity but reduced the induction by insulin to
1.8-fold vs. 7.9-fold for WT. As before, destruction of the SRE
(m24) reduced basal transcription but permitted a 6.3-fold
induction by insulin. Mutations disrupting LXRE1, LXRE2, and
SRE in the same plasmid (m34) severely reduced basal activity
and abolished insulin-mediated activation of the SREBP-1c
promoter.
In light of the requirement for the LXREs in insulin activation
of the SREBP-1c promoter, we next examined insulin-mediated
activation in the absence or presence of T0901317, a nonsterol
synthetic LXR ligand (Fig. 4). With the WT promoter,
T0901317, insulin, and the combination of T0901317 plus insulin
increased transcription by 34-, 11-, and 44-fold, respectively.
Mutating both LXREs (m31) abolished activation by T0901317
and severely reduced the insulin response without affecting the
basal activity. In contrast, mutating the SRE (m24) reduced the
basal and insulin-stimulated SREBP-1c promoter activities by
80% but reduced only slightly the fold induction by insulin
(1.40.2  7-fold vs. 11-fold for WT). Despite the reduction in
basal activity, the SRE mutant showed a normal relative induc-
tion by T0901317 (44-fold vs. 34-fold for WT) and the insulin–
T0901317 combination (49-fold induction). Mutating both
LXREs and SRE in the same plasmid (m34) reduced the basal
promoter activity to 20% of WT and abolished activation by
insulin or T0901317 or the combination.
Polyunsaturated fatty acids, such as arachidonic acid, have the
potential to reduce Srebp-1c transcription by two mechanisms: (i)
they bind to LXR, where they function as competitive antag-
onists (17), and (ii) they inhibit the proteolytic activation of
SREBP-1 isoforms, thereby potentially interfering with feed-
forward stimulation of Srebp-1c transcription through the SRE
(27). Fig. 5 shows an experiment in which we tested the effect of
100 M arachidonic acid on basal and insulin-stimulated tran-
scription driven by the SREBP-1c promoter in hepatocytes. With
the WT promoter, arachidonic acid reduced basal transcription
by 70% and severely blunted the response to insulin (Fig. 5A).
When the two LXREs were disrupted (Fig. 5B), basal transcrip-
tion was unaffected. Arachidonic acid reduced transcription to
a somewhat lesser extent (40%). As expected, with this plasmid
the response to insulin was blunted (only 2-fold), and this was
slightly reduced by arachidonic acid. As seen previously, the
SRE() plasmid had reduced basal transcription and a pre-
served relative response to insulin (Fig. 5C). This response was
Fig. 2. Nucleotide sequences (A), relative transcriptional activities (B), and fold induction (C) of WT and mutant mouse SREBP-1c promoters in primary rat
hepatocytes. (A) The sequence of a portion of the normal SREBP-1c promoter is shown at the top and numbered according to a convention in which the A of
the ATG initiation codon of mouse SREBP-1c is  1. The putative binding sites for LXR (LXRE1 and LXRE2), NF-Y, SREBP (SRE), and Sp1 and the TATA-like sequence
are underlined. The transcription initiation site is indicated by an arrow. Below the sequence of the WT promoter are shown 30 overlapping scramble mutations
that are separately introduced into the DNA by site-directed oligonucleotide mutagenesis as described in Methods. The names of the mutant plasmids, m1–m30,
are denoted on the left. The mutant scrambled sequence that was introduced is shown below the normal promoter sequence. (B) The height of each bar
represents the relative luciferase activity of plasmid D (WT) or the indicated mutant plasmid (m1–m30) in transfected hepatocytes cultured in the absence (shaded
bar) or presence (open bar) of insulin as described in Methods. The relative luciferase activity of the WT promoter (plasmid D) in the presence of insulin (mean
of 12 independent experiments) was arbitrarily assigned a value of 1.0. Each bar for mutant promoters m1–m30 represents mean  SEM of three to six
independent transfections. (C) The data in B were replotted to show the fold induction of the various promoters by insulin. The fold induction was calculated
as the ratio of normalized luciferase activity in the presence of insulin to that in the absence of insulin. The luciferase activity of each promoter in the absence
of insulin was arbitrarily assigned a value of 1.0.
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nearly abolished by arachidonic acid. Because this plasmid does
not respond to SREBPs, the ability of arachidonic acid to block
insulin activation must be attributable to its inhibition of LXRs.
When the LXREs and the SRE were both disrupted, basal and
insulin-stimulated transcription were severely reduced and there
was little effect of arachidonic acid (Fig. 5D).
Discussion
The data in this paper indicate that the insulin induction of
Srebp-1c transcription in rat hepatocytes requires a cooperative
interaction between the SRE and the two LXR binding sites. The
SRE appears to play a permissive role. Disruption of this
element severely reduces basal levels of transcription, but insulin
is still able to increase this low level of activity by 4- to 7-fold
(Figs. 2–5). On the other hand, disruption of both LXREs lowers
basal transcription rates only slightly but severely disrupts the
response to insulin. This observation is illustrated by the results
with mutant m31 in Figs. 3B, 4, and 5. The slight insulin
stimulation of this mutant plasmid might be attributable to the
increase in nuclear SREBPs that is to be expected from the effect
of insulin on endogenous SREBPs in these hepatocytes. This
conclusion is supported by the finding that the insulin response
is abolished when the SRE and the LXREs are all mutated.
These data suggest that insulin acts primarily by increasing the
ability of LXR or LXR to activate the SREBP-1c promoter.
This conclusion is supported by the observation that arachidonic
acid, an LXR antagonist, blocks insulin activation even when the
SRE is mutated. The activation of LXRs by insulin appears to
be relatively specific for the SREBP-1c promoter because insulin
does not increase transcription of other LXR-responsive genes
such as those encoding the sterol transporters Abcg5 and Abcg8.
In vivo studies in livers of rats and mice also have shown that
insulin does not increase expression of Abcg5 and Abcg8 (28, 29),
whereas it markedly increases expression of Srebp-1c (7).
In principle, insulin might activate LXRs by stimulating the
production of an activating ligand such as an oxygenated sterol
(15, 16) by increasing the activity of a coactivator such as PGC-1
(30, 31) or ASC-2 (32), or by increasing the activity of LXR itself.
The current data provide a clue that insulin may act by producing
an activating ligand. This clue comes from the result in Fig. 4, in
Fig. 3. Mutations of LXRE1, LXRE2, and SRE in SREBP-1c promoter sequence
reduce insulin-induced activation in primary rat hepatocytes. The indicated
WT or scramble mutant plasmid was transfected into hepatocytes, incubated
with or without 100 nM insulin, and assayed for dual luciferase activity as
described in the legend to Fig. 1. Each value represents the mean  SEM of
three independent transfection experiments (each assayed in duplicate). In
each experiment, all of the mutant plasmids were studied. The normalized
luciferase activity of the WT promoter in the absence of insulin was arbitrarily
assigned a value of 1.0. The numbers above the bars refer to the fold increase
by insulin.
Fig. 4. Maximal activation of SREBP-1c promoter by LXR agonist (T0901317)
requires intact SRE as well as LXRE1 and LXRE2. The WT plasmid D (A) or the
indicated mutant plasmid (B, plasmid m31; C, m24; D, m34) was transfected
into primary rat hepatocytes as described in Fig. 1 and incubated in the
absence or presence of 1 M T0901317 or 100 nM insulin or both as indicated.
After incubation for 21 h, the cells were harvested and assayed for dual
luciferase activities. Relative luciferase activity was calculated as described in
Fig. 3. The numbers above the bars refer to the fold increase relative to the WT
value in the absence of addition. Each value represents the mean  SEM of
three independent transfection experiments (each assayed in duplicate).
Fig. 5. Suppression of SREBP-1c promoter activity by arachidonic acid is
mediated through the LXR elements. The WT plasmid D (A) or the indicated
mutant plasmid (B, plasmid m31; C, m24; D, m34) was transfected into primary
rat hepatocytes as described in Fig. 1 and incubated without or with 100 M
sodium arachidonate in the absence or presence of 100 nM insulin in medium
B containing 0.1% (wtvol) BSA. After incubation for 21 h, the cells were
harvested and assayed for dual luciferase activities. Relative luciferase activity
was calculated as described in Fig. 3. The numbers above the bars refer to the
fold increase relative to the WT value in the absence of addition. Each value
represents the mean  SEM of three independent transfection experiments
(each assayed in duplicate).








which we added T0901317, a strong LXR agonist. This com-
pound activated the SREBP-1c reporter construct by a massive
34-fold, and there was little further activation when insulin was
added on top of T0901317 (Fig. 4A). If insulin were acting by
increasing the intrinsic activity of LXR or by activating a
coactivator, we would have expected that insulin would have
synergized with T0901317. The fact that insulin did not further
activate when the LXR sites are already occupied suggests that
insulin itself creates a ligand for LXR or for its heterodimerizing
partner, RXR, which is known to be activated by 9-cis-retinoic
acid (33). Further studies will be necessary to test this hypothesis.
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